Drug
Bnt3210
Bnt3210: highest development phase Phase 1/2, developed by BioNTech. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT3210 NCT07886684 | Phase 1/2 | Advanced Solid Tumors |
Latest
No recent events.
Follow Bnt3210 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.